Kuros Biosciences AG Statistics

Total Valuation

Kuros Biosciences AG has a market cap or net worth of CHF 913.02 million. The enterprise value is 900.71 million.

Market Cap	913.02M
Enterprise Value	900.71M

Important Dates

The last earnings date was Thursday, November 7, 2024.

Earnings Date	Nov 7, 2024
Ex-Dividend Date	n/a

Share Statistics

Kuros Biosciences AG has 37.57 million shares outstanding. The number of shares has decreased by -17.17% in one year.

Current Share Class	n/a
Shares Outstanding	37.57M
Shares Change (YoY)	-17.17%
Shares Change (QoQ)	-43.09%
Owned by Insiders (%)	24.39%
Owned by Institutions (%)	16.92%
Float	25.19M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	13.45
PB Ratio	8.52
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-101.36
EV / Sales	17.14
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-277.40

Financial Position

The company has a current ratio of 2.73, with a Debt / Equity ratio of 0.03.

Current Ratio	2.73
Quick Ratio	2.08
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.60
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -14.32% and return on invested capital (ROIC) is -4.54%.

Return on Equity (ROE)	-14.32%
Return on Assets (ROA)	-3.77%
Return on Capital (ROIC)	-4.54%
Revenue Per Employee	495,679
Profits Per Employee	-83,830
Employee Count	80
Asset Turnover	0.68
Inventory Turnover	1.14

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +565.75% in the last 52 weeks. The beta is 0.87, so Kuros Biosciences AG's price volatility has been lower than the market average.

Beta (5Y)	0.87
52-Week Price Change	+565.75%
50-Day Moving Average	22.85
200-Day Moving Average	13.04
Relative Strength Index (RSI)	49.02
Average Volume (20 Days)	400,701

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kuros Biosciences AG had revenue of CHF 52.54 million and -8.89 million in losses. Loss per share was -0.31.

Revenue	52.54M
Gross Profit	46.11M
Operating Income	-4.69M
Pretax Income	-7.37M
Net Income	-8.89M
EBITDA	-3.05M
EBIT	-4.69M
Loss Per Share	-0.31

Full Income Statement

Balance Sheet

The company has 14.28 million in cash and 1.96 million in debt, giving a net cash position of 12.31 million or 0.33 per share.

Cash & Cash Equivalents	14.28M
Total Debt	1.96M
Net Cash	12.31M
Net Cash Per Share	0.33
Equity (Book Value)	60.18M
Book Value Per Share	2.85
Working Capital	21.08M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.42 million and capital expenditures -832,000, giving a free cash flow of -3.25 million.

Operating Cash Flow	-2.42M
Capital Expenditures	-832,000
Free Cash Flow	-3.25M
FCF Per Share	-0.09

Full Cash Flow Statement

Margins

Gross margin is 87.77%, with operating and profit margins of -8.92% and -16.91%.

Gross Margin	87.77%
Operating Margin	-8.92%
Pretax Margin	-14.03%
Profit Margin	-16.91%
EBITDA Margin	-5.80%
EBIT Margin	-8.92%
FCF Margin	-6.18%

Dividends & Yields

Kuros Biosciences AG does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	17.17%
Shareholder Yield	17.17%
Earnings Yield	-1.28%
FCF Yield	-0.36%

Stock Splits

The last stock split was on June 23, 2016. It was a reverse split with a ratio of 0.01.

Last Split Date	Jun 23, 2016
Split Type	Reverse
Split Ratio	0.01

Scores

Kuros Biosciences AG has an Altman Z-Score of 6.08.

Altman Z-Score	6.08
Piotroski F-Score	n/a